Compare VET & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VET | IMTX |
|---|---|---|
| Founded | 1994 | N/A |
| Country | Canada | Germany |
| Employees | N/A | 407 |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 2004 | N/A |
| Metric | VET | IMTX |
|---|---|---|
| Price | $10.59 | $8.84 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $15.00 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 1.3M | 338.9K |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | ★ 2.84% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.07 | N/A |
| Revenue Next Year | $3.40 | $25.91 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.00 | $5.05 |
| 52 Week High | $14.82 | $12.41 |
| Indicator | VET | IMTX |
|---|---|---|
| Relative Strength Index (RSI) | 56.49 | 39.55 |
| Support Level | $10.20 | $8.99 |
| Resistance Level | $10.92 | $10.67 |
| Average True Range (ATR) | 0.37 | 0.45 |
| MACD | 0.25 | -0.04 |
| Stochastic Oscillator | 62.66 | 1.33 |
Vermilion Energy Inc is an international oil and gas-producing company. The company engages in full-cycle exploration and production programs that focus on the acquisition, exploration, and development of liquids-rich natural gas in Canada and conventional natural gas in Europe while optimizing low-decline oil assets. Its operating segments are: Canada, France, Netherlands, Germany, Ireland, Australia, and CEE, each representing the oil and gas exploration operations at its assets located in these regions. The company mainly derives revenue from the production and sale of petroleum and natural gas. The majority of its revenue is generated from Canada, where the company's operations are mainly focused on the Deep Basin trend in the West Pembina region of Alberta and on the Mica property.
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.